Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews · Kidney and Transplant · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 4 · 57.1%High 0 · 0%

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Complete or partial remission · minimal change disease in adults with nephrotic syndrome

Calcineurin inhibitors ± oral steroids showed no clear difference in complete or partial remission time frame: 3 to 6 months compared with oral steroids alone (moderate certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 1.01 [0.96, 1.05]
4 studies · 269 participants
Moderate

Mycophenolate sodium + oral steroids vs oral steroids alone

Complete or partial remission · minimal change disease in adults with nephrotic syndrome

Mycophenolate sodium + oral steroids showed no clear difference in complete or partial remission Time frame: 24 weeks to end of treatment compared with oral steroids alone (moderate certainty).

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
RR 0.92 [0.75, 1.12]
2 studies · 134 participants
Moderate

Intravenous ± oral steroids vs oral steroids alone

Complete or partial remission · minimal change disease in adults with nephrotic syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Scheduled surveillance vs clinical monitoring alone

Access thrombosis/vascular complication · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.

Scheduled surveillance showed no clear difference in risk of access thrombosis compared with clinical monitoring alone (moderate certainty).

1 finding from 1 review

Pre‐emptive correction for haemodialysis arteriovenous access stenosis 2016 · Cochrane Headline outcomes only
RR 0.95 [0.8, 1.12]
8 studies · 697 participants
Moderate

Scheduled surveillance vs clinical monitoring alone

Rate of angiograms · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.

Scheduled surveillance may leads to higher rate of angiograms compared with clinical monitoring alone (low certainty).

1 finding from 1 review

Pre‐emptive correction for haemodialysis arteriovenous access stenosis 2016 · Cochrane Headline outcomes only
RR 1.78 [1.18, 2.67]
5 studies · 539 participants
Low

Scheduled surveillance vs clinical monitoring alone

Risk of access loss · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.

Scheduled surveillance showed no clear difference in risk of access loss compared with clinical monitoring alone (moderate certainty).

1 finding from 1 review

Pre‐emptive correction for haemodialysis arteriovenous access stenosis 2016 · Cochrane Headline outcomes only
RR 0.9 [0.71, 1.15]
6 studies · 662 participants
Moderate

Scheduled surveillance vs clinical monitoring alone

All‐cause mortality · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.

Scheduled surveillance showed no clear difference in mortality compared with clinical monitoring alone (low certainty).

1 finding from 1 review

Pre‐emptive correction for haemodialysis arteriovenous access stenosis 2016 · Cochrane Headline outcomes only
RR 1.38 [0.9, 2.11]
5 studies · 586 participants
Low